Other medicines, foods and herbal products can change how Pioglitazone works. Everything on this page comes from Pioglitazone's own FDA-approved label — the same source as the main guide.
Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.
An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t ½ ) of pioglitazone. Therefore, the maximum recommended dose of pioglitazone tablets is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors .
An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with pioglitazone tablets, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for pioglitazone tablets .
Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate . The clinical relevance of this decrease is unknown; however, when pioglitazone tablets and topiramate are used concomitantly, monitor patients for adequate glycemic control.
Pioglitazone's label names 2 medicines that NepalDoc also covers.
These medicines named in Pioglitazone's label have interaction pages of their own:
• Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit pioglitazone tablets dose to 15 mg daily. • CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. • Topiramate may decrease pioglitazone concentrations.
7.1 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t ½ ) of pioglitazone. Therefore, the maximum recommended dose of pioglitazone tablets is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors .
7.2 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with pioglitazone tablets, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for pioglitazone tablets .
7.3 Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate . The clinical relevance of this decrease is unknown; however, when pioglitazone tablets and topiramate are used concomitantly, monitor patients for adequate glycemic control.
Pioglitazone guide · All interaction pages · Medicines A–Z
This page summarises Pioglitazone's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.